✦ LIBER ✦

Clinical course after change of immunomodulating therapy in relapsing–remitting multiple sclerosis

✍ Scribed by C. Caon; M. Din; W. Ching; A. Tselis; R. Lisak; O. Khan

Book ID: 111064644
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 96 KB
Volume: 13
Category: Article
ISSN: 1351-5101
DOI: 10.1111/j.1468-1331.2006.01273.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical significance of antibodies to i

Clinical significance of antibodies to interferon beta therapy in patients with relapsing–remitting multiple sclerosis

✍ Klaus Bendtzen 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 108 KB

A post-marketing study on immunomodulati

A post-marketing study on immunomodulating treatments for relapsing-remitting multiple sclerosis in Lombardia: preliminary results

✍ C. Milanese; E. Beghi; L. Giordano; L. La Mantia; N. Mascoli; P. Confalonieri; a 📂 Article 📅 2005 🏛 Springer Milan 🌐 English ⚖ 61 KB

Randomised placebo-controlled trial of m

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis

✍ Franz Fazekas; Florian Deisenhammer; Siegrid Strasser-Fuchs; Gerhard Nahler; Bru 📂 Article 📅 1997 🏛 The Lancet 🌐 English ⚖ 46 KB

Natalizumab is effective as second line

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

✍ N. Putzki; K. Kollia; S. Woods; E. Igwe; H. C. Diener; V. Limmroth 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

fMRI changes in relapsing-remitting mult

fMRI changes in relapsing-remitting multiple sclerosis patients complaining of fatigue after IFNβ-1a injection

✍ Maria A. Rocca; Federica Agosta; Bruno Colombo; Domenico M. Mezzapesa; Andrea Fa 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB

## Abstract If fatigue in multiple sclerosis (MS) is related to an abnormal activation of the sensorimotor brain network, the activity of such a network should vary with varying fatigue. We studied 22 patients treated with interferon beta 1a (IFNβ‐1a; Avonex, Biogen, Cambridge, MA) with no fatigue

Improvement of health-related quality of

Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2

✍ Peter Joseph Jongen; Christian Sindic; Herwig Carton; Cees Zwanikken; Wim Lemmen 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 158 KB